Dolutegravir is an HIV integrase strand transfer inhibitor (INSTI) that does not require pharmacokinetic boosting, has a long half-life allowing for once-daily dosing in treatment-naive patients ...

Current INSTI vs protease inhibitor or NNRTI use is linked to an increased risk for diabetes, which is slightly attenuated when adjusted for changes in BMI.

Dolutegravir is an HIV integrase strand transfer inhibitor (INSTI) that does not require pharmacokinetic boosting, has a long half-life allowing for once-daily dosing in treatment-naive patients ...

Gilead Sciences Inc. recently disclosed details on the work that led to the discovery of elunonavir (GS-1156), an unboosted HIV protease inhibitor currently in phase I studies.

Historically, most people started HIV treatment with two drugs from the NRTI class combined with either one NNRTI, one protease inhibitor or one integrase inhibitor – hence, ‘triple therapy’.

Gilead Sciences’ capsid inhibitor lenacapavir has the most competitive potential in long-acting combination regimens in HIV, ...

HIV-1 entry into cells is an attractive target for new antiviral agents. But will inhibitors aimed at the CCR5 co-receptor force HIV-1 to evolve more virulent forms? Other targets for entry ...

These protease inhibitors, despite their side effects and ... but at a portal through which HIV enters white blood cells and attacks the immune system. Scientists in 1996 identified the portal ...

In a session at AIDS 2024, the International AIDS Conference, global leaders and community advocates gathered to discuss why ...

There is a limited number of studies on interactions between GHB and anti-HIV drugs. These studies reported higher exposure to GHB, which may lead to higher levels of GHB. Due to the close relation ...